Q-omics provides the consensus-scored ZNF764 profile across patient tissues and cancer cell-line models. ZNF764 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF764 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ZNF764 RNA expression shows 20,317 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, HNSC, and KIRP as cancer lineages where ZNF764 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF764 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF764 survival associations across molecular data types. ZNF764 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF764 RNA expression–survival associations across cancer types. High ZNF764 expression shows unfavorable associations in LIHC, KIRP and BLCA, but favorable associations in KIRC, HNSC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF764 RNA expression.
This table summarizes ZNF764 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF764. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF764 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, KIRP, LIHC and BLCA. The HNSC box plot shows higher ZNF764 RNA expression in tumor versus normal tissue (log2 FC = +0.763, t-test p < 0.001).
This table shows molecular features associated with ZNF764 in patient tissues and cancer cell lines. In patient samples, ZNF764 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF764 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
